Insights
Insights From Our Experts
Articles
The Next Frontier Isn’t Automation. It’s Orchestration.
Conversations about AI in commercial pharma have largely centered on automation and efficiency gains. How can we generate content faster? Analyze data faster? Produce insights faster? These are important advancements, but they focus on individual activities…
Shaping the Future of Pharmaceutical Market Access
Market access has always been complex, but today’s environment is fundamentally different. Rising pricing pressures, restrictive utilization management, and shifting policies have created increasingly complicated patient journeys. In a recent interview with Pharmaceutical Executive, Jen Norton,…
EVERSANA Recognized as a Great Place to Work® Across Six Countries
EVERSANA is proud to announce that we have once again been recognized as a Great Place to Work®, earning certification across six countries: the United States, Canada, India, Italy, Spain and the United Kingdom. This year’s…
Understanding the Role of AI in Government Pricing Compliance: New Risks and New Advantages
In the last few years, AI has evolved from a pipe dream into a world of possibilities and now has transitioned into a catalyst for change. AI will revolutionize how we monitor, document, and analyze information…
The Most-Favored-Nation Model, One Year Later: Where Do Globe, Guard, and Generous Stand Today?
A year ago, the debate surrounding the Most-Favored-Nation (MFN) model centered on a fundamental question: would international reference pricing create a more sustainable global benchmark, or introduce new risks across pharmaceutical markets? At the time, concerns…
CMS Bona Fide Service Fee Requirements: Manufacturer Challenges Under the CY 2026 Final Rule
The Centers for Medicare & Medicaid Services’ CY 2026 Physician Fee Schedule Final Rule introduced new documentation requirements for manufacturers reporting Average Sales Price (ASP) for Medicare Part B drugs. Among the most significant changes are…
Understanding MFN Pricing: Key Considerations for Pharma Manufacturers
Recent developments surrounding Most-Favored-Nation (MFN) pricing continue to reshape discussions around pricing and access strategy across the pharmaceutical industry. In a recent interview with Pharmaceutical Executive, Alan Crowther, General Manager, Global Pricing & Access at EVERSANA,…
EVERSANA’s Intelligent Copay Solution Recognized with PM360 Innovation Award
EVERSANA is proud to announce that our Intelligent Copay Solution has been recognized as a winner in the Core Business Processes category of the PM360 Innovation Awards. The award recognizes innovations that are helping transform how…
One Year of EVERSANA’s AI Agency: What We Learned at Google’s New York Headquarters
One year after launching AI Agency, EVERSANA joined Google Cloud and more than 80 life sciences organizations at Google’s New York headquarters to explore a question facing the industry: How do pharmaceutical companies move from AI…
The Hidden Cost of Late Evidence Planning
Many pharmaceutical teams cross the regulatory finish line only to hit a wall: market access demands a head-to-head comparison or real-world data that simply doesn’t exist. Treating Evidence Generation Planning (EGP) as a reactive, late-stage checklist rather than…